Onyx Pharmaceuticals Inc. (ONXX) announced after the bell Wednesday that the FDA's Oncologic Drugs Advisory Committee determined by a vote of 11-0 that, in patients with relapsed and refractory multiple myeloma who have received at least two prior lines of therapy that included a proteasome inhibitor and an immunomodulatory agent, the benefit-risk assessment is favorable for the use of Kyprolis.
Onyx Pharmaceuticals has gapped open dramatically higher Wedneday and is now up 17.50 at $62.08 on strong volume. The stock has surged to a new high for the year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.